Search

Your search keyword '"Christine Person-Tacnet"' showing total 4 results
Start Over Author "Christine Person-Tacnet"
4 results on '"Christine Person-Tacnet"'

1. Women and COPD: do we need more evidence?

Author

Christophe Gut-Gobert, Arnaud Cavaillès, Adrien Dixmier, Stéphanie Guillot, Stéphane Jouneau, Christophe Leroyer, Sylvain Marchand-Adam, David Marquette, Jean-Claude Meurice, Nicolas Desvigne, Hugues Morel, Christine Person-Tacnet, and Chantal Raherison

Subjects
Diseases of the respiratory system, RC705-779
Abstract

The increasingly female face of chronic obstructive pulmonary disease (COPD) prevalence among women has equalled that of men since 2008, due in part to increased tobacco use among women worldwide and exposure to biomass fuels. This finding is supported by a number of characteristics. There is evidence of susceptibility to smoking and other airborne contaminants, along with epidemiological and phenotypic manifestations. COPD has thus become the leading cause of death in women in the USA. The clinical presentation is characterised by increasingly pronounced dyspnoea with a marked tendency towards anxiety and depression, undernutrition, nonsmall cell lung cancer (especially adenocarcinoma) and osteoporosis. Quality of life is also more significantly impacted. The theories advanced to explain these differences involve the role played by oestrogens, impaired gas exchange in the lungs and smoking habits. While these differences require appropriate therapeutic responses (smoking cessation, pulmonary rehabilitation, long-term oxygen therapy), barriers to the treatment of women with COPD include greater under-diagnosis than in men, fewer spirometry tests and medical consultations. Faced with this serious public health problem, we need to update and adapt our knowledge to the epidemiological changes.

Published
2019
Full Text
View/download PDF

2. Comorbidities of COPD

Author

Arnaud Cavaillès, Graziella Brinchault-Rabin, Adrien Dixmier, François Goupil, Christophe Gut-Gobert, Sylvain Marchand-Adam, Jean-Claude Meurice, Hugues Morel, Christine Person-Tacnet, Christophe Leroyer, and Patrice Diot

Subjects
Diseases of the respiratory system, RC705-779
Abstract

By 2020, chronic obstructive pulmonary disease (COPD) will be the third cause of mortality. Extrapulmonary comorbidities influence the prognosis of patients with COPD. Tobacco smoking is a common risk factor for many comorbidities, including coronary heart disease, heart failure and lung cancer. Comorbidities such as pulmonary artery disease and malnutrition are directly caused by COPD, whereas others, such as systemic venous thromboembolism, anxiety, depression, osteoporosis, obesity, metabolic syndrome, diabetes, sleep disturbance and anaemia, have no evident physiopathological relationship with COPD. The common ground between most of these extrapulmonary manifestations is chronic systemic inflammation. All of these diseases potentiate the morbidity of COPD, leading to increased hospitalisations and healthcare costs. They can frequently cause death, independently of respiratory failure. Comorbidities make the management of COPD difficult and need to be evaluated and treated adequately.

Published
2013
Full Text
View/download PDF

3. Women and COPD: do we need more evidence?

Author

Sylvain Marchand-Adam, Christophe Gut-Gobert, Hugues Morel, Arnaud Cavaillès, David Marquette, Christine Person-Tacnet, Christophe Leroyer, Stéphane Jouneau, Nicolas Desvigne, Stéphanie Guillot, Jean-Claude Meurice, A. Dixmier, Chantal Raherison, Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Régional d'Orléans (CHRO), CHU Pontchaillou [Rennes], Institut de recherche en santé, environnement et travail (Irset), Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Institut National de la Santé et de la Recherche Médicale (INSERM)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université d'Angers (UA), Pathologies Respiratoires : Protéolyse et Aérosolthérapie, Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre hospitalier Bretagne Atlantique (Morbihan) (CHBA), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Novartis Pharma, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), CHU Bordeaux [Bordeaux], Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), and Jonchère, Laurent

Subjects
Male, medicine.medical_treatment, Pulmonary Disease, Chronic Obstructive, 0302 clinical medicine, Cost of Illness, Risk Factors, Epidemiology, Prevalence, 030212 general & internal medicine, Lung, Depression (differential diagnoses), Cause of death, Aged, 80 and over, COPD, medicine.diagnostic_test, Smoking, Age Factors, Middle Aged, Prognosis, 3. Good health, Phenotype, Anxiety, Female, medicine.symptom, Pulmonary and Respiratory Medicine, Spirometry, Adult, medicine.medical_specialty, Adolescent, Risk Assessment, 03 medical and health sciences, Young Adult, Sex Factors, medicine, Humans, [SDV.EE.SANT] Life Sciences [q-bio]/Ecology, environment/Health, Pulmonary rehabilitation, Healthcare Disparities, Sex Distribution, Intensive care medicine, Aged, [SDV.EE.SANT]Life Sciences [q-bio]/Ecology, environment/Health, lcsh:RC705-779, business.industry, Health Status Disparities, lcsh:Diseases of the respiratory system, medicine.disease, 030228 respiratory system, Quality of Life, Smoking cessation, business
Abstract

International audience; The increasingly female face of chronic obstructive pulmonary disease (COPD) prevalence among women has equalled that of men since 2008, due in part to increased tobacco use among women worldwide and exposure to biomass fuels. This finding is supported by a number of characteristics. There is evidence of susceptibility to smoking and other airborne contaminants, along with epidemiological and phenotypic manifestations. COPD has thus become the leading cause of death in women in the USA. The clinical presentation is characterised by increasingly pronounced dyspnoea with a marked tendency towards anxiety and depression, undernutrition, nonsmall cell lung cancer (especially adenocarcinoma) and osteoporosis. Quality of life is also more significantly impacted. The theories advanced to explain these differences involve the role played by oestrogens, impaired gas exchange in the lungs and smoking habits. While these differences require appropriate therapeutic responses (smoking cessation, pulmonary rehabilitation, long-term oxygen therapy), barriers to the treatment of women with COPD include greater under-diagnosis than in men, fewer spirometry tests and medical consultations. Faced with this serious public health problem, we need to update and adapt our knowledge to the epidemiological changes.

Published
2019

4. Comorbidities of COPD

Author

François Goupil, Christophe Gut-Gobert, Christophe Leroyer, Sylvain Marchand-Adam, Patrice Diot, Hugues Morel, Graziella Brinchault-Rabin, A. Dixmier, Jean-Claude Meurice, Arnaud Cavaillès, Christine Person-Tacnet, Service de pneumologie [Nantes], Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire [Rennes], Centre Hospitalier Régional d'Orléans (CHRO), Centre Hospitalier du Mans, Département de Médecine Interne et Pneumologie [Brest] (DMIP - Brest), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Pathologies Respiratoires : Protéolyse et Aérosolthérapie, Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Hopital Broussais de Saint-Malo, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), and Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, MESH: Comorbidity, Disease, Comorbidity, Systemic inflammation, Risk Assessment, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, MESH: Pulmonary Disease, Chronic Obstructive/therapy, 03 medical and health sciences, Pulmonary Disease, Chronic Obstructive, 0302 clinical medicine, Predictive Value of Tests, Risk Factors, Internal medicine, medicine, Humans, 030212 general & internal medicine, Risk factor, 2. Zero hunger, Inflammation, lcsh:RC705-779, COPD, business.industry, Smoking, MESH: Pulmonary Disease, Chronic Obstructive/diagnosis, lcsh:Diseases of the respiratory system, medicine.disease, Prognosis, 3. Good health, respiratory tract diseases, 030228 respiratory system, Respiratory failure, MESH: Inflammation/diagnosis, Heart failure, MESH: Inflammation/therapy, Physical therapy, medicine.symptom, Metabolic syndrome, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; By 2020, chronic obstructive pulmonary disease (COPD) will be the third cause of mortality. Extrapulmonary comorbidities influence the prognosis of patients with COPD. Tobacco smoking is a common risk factor for many comorbidities, including coronary heart disease, heart failure and lung cancer. Comorbidities such as pulmonary artery disease and malnutrition are directly caused by COPD, whereas others, such as systemic venous thromboembolism, anxiety, depression, osteoporosis, obesity, metabolic syndrome, diabetes, sleep disturbance and anaemia, have no evident physiopathological relationship with COPD. The common ground between most of these extrapulmonary manifestations is chronic systemic inflammation. All of these diseases potentiate the morbidity of COPD, leading to increased hospitalisations and healthcare costs. They can frequently cause death, independently of respiratory failure. Comorbidities make the management of COPD difficult and need to be evaluated and treated adequately. Extrapulmonary comorbidities are common in COPD and influence prognosis; we propose an exhaustive comorbidities review

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results